Abstract 3337
Background
Family caregivers of cancer patients report high burden leading to poor emotional and physical health. Knowledge of predisposing factors could contribute to its prevention or early detection. The aim of this study was to identify the factors related to caregiver burden among caregivers of cancer patients.
Methods
90 cancer patients hospitalised in two oncological wards in Crete, Greece and their primary caregivers (PCs) were included in the study. They both provided their demographics, while PCs completed the Bakas Caregiving Outcomes Scale (BCOS), comprising 15 self-rated items (7-point response scale with reduced BCOS scores implying higher burden) and the Hospital Anxiety and Depression Scale (HADS), comprising 14 self-rated items in a 4-point scale (0-3).
Results
Most patients were male (52.2%) and most PCs were female (67.8%), aged 50 to 74 years old (52.2% and 54.4% respectively). The majority of PCs (44.3%) were spouses. The mean of burden using the BCOS was 56.7 (SD 10.9) (range 22-100), 75.6% experienced no burden (total score > 52.5), while 24.4% reported high burden (total score < 52.5). High level of anxiety (≥ 11) using the HADS was reported by 55.6% of PCs and high level of depression (≥ 11) by 20%. The correlations between BCOS and HAD-Anxiety (r=-0.401, p < 0.001) and BCOS and HAD-Depression (r=-0.402, p < 0.001) were negatively moderate. Older age PCs appear to experience higher burden (r=-0.278, p = 0.008) and depression (r = 0.372, p < 0.001), while the duration of caregiving also imposes more anxiety (r=-0.322, p = 0.002) and depression (r = 0.262, p = 0.013). On the other hand, depression correlates negatively with the educational background of both patients (r=-0.247, p = 0,019) and caregivers (r=-0.283, p = 0.007).
Conclusions
Primary caregiver anxiety, depression, age, the duration of caregiving and the patient and caregiver educational background are factors related to caregiver burden. Larger sample studies are needed to better identify the factors affecting caregiver burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract